Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02945176
Other study ID # ARGOS-KP01
Secondary ID CIV-14-09-012725
Status Completed
Phase N/A
First received September 7, 2016
Last updated August 15, 2017
Start date March 2015
Est. completion date June 14, 2017

Study information

Verified date August 2017
Source Implandata Ophthalmic Products GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely. It is intended to be used together with the hand-held Mesograph reading device to telemetrically measure the intraocular pressure (IOP) of patients with a BKPro.

The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients undergoing concomitant implantation of a BKPro and an ARGOS-IO sensor over the 12 month period beginning at implantation.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 14, 2017
Est. primary completion date June 14, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Male or female aged = 18 and = 80 years on the day of screening

2. Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularized cornea AND either a verifiable history of two or more prior failed corneal transplant procedures or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.

3. Axial length > 21 mm

4. Ability and willingness to attend all scheduled visits and comply with all study procedures

Exclusion Criteria:

1. Reasonable chance of success with traditional keratoplasty

2. Current retinal detachment

3. Connective tissue diseases

4. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation

5. History of ocular or periocular malignancy

6. History of extensive keloid formation

7. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, or silicone (component of the device)

8. Presence of another active medical eye implant and/or other active medical implants in the head/neck region

9. Signs of current infection, including fever and current treatment with antibiotics

10. Severe generalized disease that results in a life expectancy shorter than a year

11. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device

12. Currently pregnant or breastfeeding

13. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device

14. Intraoperative complication that would preclude implantation of the study device

15. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.

Previous or concurrent enrollment of the contralateral eye in this clinical study.

Study Design


Intervention

Device:
ARGOS-IO system
This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.

Locations

Country Name City State
Germany Zentrum für Augenheilkunde der Universität zu Köln Cologne
Germany MVZ Prof. Neuhann Munich

Sponsors (1)

Lead Sponsor Collaborator
Implandata Ophthalmic Products GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the ARGOS-IO pressure sensor in the first 12 months following implantation Number of subjects experiencing at any time during the first 12 months a device related serious adverse event (SAE) defined as any adverse event that both:
is considered by the investigator to have a possible, probable or definite relationship to the device
AND that leads to any following
death
a serious deterioration in the health of the subject that results in a life-threatening illness or injury or a permanent impairment of a body structure or function, or that requires medical/surgical intervention to prevent such
hospitalization or prolongation of existing hospitalization
fetal distress or death or a congenital abnormality or birth defect.
12 months
Primary Tolerability of the ARGOS-IO pressure sensor in the first 12 months following implantation Number of subjects experiencing at any time during the first 12 months a device related SAE defined as any adverse event that both:
is considered by the investigator to have a possible, probable or definite relationship to the device
AND that leads to any following
death
a serious deterioration in the health of the subject that results in a life-threatening illness or injury or a permanent impairment of a body structure or function, or that requires medical/surgical intervention to prevent such
hospitalization or prolongation of existing hospitalization
fetal distress or death or a congenital abnormality or birth defect.
12 months
Primary Performance of the ARGOS-IO system compared to manometry in the first 12 months following implantation Level of agreement between IOP measurements made using manometry (mmHg) and the ARGOS-IO system (mmHg) over the first 12 months following implantation 12 months
Secondary Safety of the ARGOS-IO pressure sensor use in the first 4, 16 and 28 weeks and 12 months following implantation Incidence, nature, seriousness, severity and duration of adverse events and adverse device events in the first 4, 16 and 28 weeks and 12 months following implantation of the ARGOS-IO pressure sensor. 4, 16 and 28 weeks and 12 months following implantation
Secondary Tolerability of the ARGOS-IO pressure sensor use in the first 4, 16 and 28 weeks and 12 months following implantation Incidence, nature, seriousness, severity and duration of adverse events and adverse device events in the first 4, 16 and 28 weeks and 12 months following implantation of the ARGOS-IO pressure sensor. 4, 16 and 28 weeks and 12 months following implantation
Secondary Level of agreement between IOP measurements made using surgical manometry (mmHg) and the ARGOS-IO system (mmHg) at 4, 16, 28 and 52 weeks following implantation 4, 16, 28 and 52 weeks following implantation
Secondary User acceptance of the implantation procedure by means of evaluation of the implantation procedure questionnaire (investigators) 4, 16, 28 and 52 weeks following implantation
Secondary User acceptance of the ARGOS-IO system at the investigational site by means of evaluation of the investigator acceptance questionnaire (investigators) 4, 16, 28 and 52 weeks following implantation
Secondary Daily IOP self-measurement profiles (subjects) 4, 16, 28 and 52 weeks following implantation
See also
  Status Clinical Trial Phase
Recruiting NCT06080490 - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Withdrawn NCT04728646 - Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes Phase 4
Suspended NCT01972438 - A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients Phase 1/Phase 2
Completed NCT01221766 - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease N/A
Recruiting NCT01764100 - Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD) Phase 1
Completed NCT00760981 - A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease Phase 1
Terminated NCT00298324 - Myfortic - Treatment for Extensive cGvHD Phase 3
Completed NCT00224874 - Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Phase 2
Completed NCT00023530 - Blood and Marrow Transplant Clinical Research Network N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Recruiting NCT05111834 - IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms N/A
Completed NCT02841995 - A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease Phase 2
Recruiting NCT06143501 - Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
Recruiting NCT04622956 - GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide Phase 1/Phase 2
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Not yet recruiting NCT06450925 - Vitamin A Supplementation in Allogeneic Stem Cell Transplantation. N/A
Not yet recruiting NCT02506231 - The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Phase 2/Phase 3
Recruiting NCT01042509 - Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease N/A